Identification of Novel Markers of Human Lung Disease
Launched by OHIO STATE UNIVERSITY · Feb 23, 2015
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking for new treatments for advanced lung diseases, particularly in patients who are on the lung transplant waiting list. Researchers want to identify new markers, which are indicators that can help in understanding and treating lung conditions better. If you're between the ages of 65 and 74 and are currently on the list for a lung transplant, you may be eligible to participate in this study. However, if you are HIV positive, you would not qualify for this trial.
If you decide to participate, you’ll be helping researchers learn more about lung diseases and potentially contribute to finding new therapies that could help others in the future. Participants in this study can expect to undergo various assessments to help researchers gather important information. Your involvement could play a crucial role in advancing treatment options for people with lung diseases.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • any one on lung transplant list
- Exclusion Criteria:
- • HIV positive
About Ohio State University
The Ohio State University (OSU) is a leading research institution dedicated to advancing health and science through innovative clinical trials. With a commitment to improving patient care and outcomes, OSU leverages its extensive resources, interdisciplinary collaboration, and expertise in diverse medical fields. The university fosters an environment of rigorous scientific inquiry, ensuring that clinical trials are conducted with the highest ethical standards and adherence to regulatory guidelines. Through its Clinical Trials Office, OSU aims to translate groundbreaking research into practical applications, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbus, Ohio, United States
Patients applied
Trial Officials
Megan Ballinger
Principal Investigator
Ohio State University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials